SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 5
Abstract
Background and aims. Secreted frizzled-related protein 5 (SFRP5) was recently described as a new adipokine protective for hepatic steatosis and other obesity-related complications in the mouse model. To date, SFRP5 expression in non-alcoholic fatty liver disease (NAFLD) has not been fully assessed in humans. We measured circulating SFRP5 levels and its expression in liver and adipose tissue, and evaluated its association with NAFLD in morbidly obese women. Material and methods. Fifty-four morbidly obese women undergoing bariatric surgery were included in the study. Liver biopsies were used for histology and hepatic triglyceride content quantification. Circulating SFRP5 levels were measured through enzyme-linked immunoabsorbent assay, and SFRP5 expression was performed in hepatic and adipose tissue (subcutaneous and visceral). Results. Although circulating SFRP5 levels showed a tendency to decrease with NAFLD progression, no significant differences were observed among non-alcoholic steatosis, steatohepatitis, and control subjects. Hepatic SFRP5 expression showed a negative correlation with hepatic triglyceride content (r = -0.349, P = 0.016 for mRNA and r = -0.291, P = 0.040 for SRFP5 protein) and ALT serum levels (r = -0.437, P = 0.001 for SRFP5 protein). In addition, hepatic SFRP5 protein levels were significantly lower in NASH than in control subjects (P = 0.006). Conclusion. This is the first study reporting an association of hepatic SFRP5 expression with NAFLD in humans.
Authors and Affiliations
Roxana Gutiérrez-Vidal, Joel Vega-Badillo, Laura M. Reyes-Fermín, Hugo A. Hernández-Pérez, Fausto Sánchez-Muñoz, Guadalupe S. López-Álvarez, Elena Larrieta-Carrasco, Itzel Fernández-Silva, Nahum Méndez-Sánchez, Armando R. Tovar, Hugo Villamil-Ramírez, Ana M. Mejía-Domínguez, Teresa Villarreal-Molina, Rogelio Hernández-Pando, Francisco Campos-Pérez, Carlos A. Aguilar-Salinas, Samuel Canizales-Quinteros
Keywords
Related Articles
- EP ID EP78492
- DOI -
- Views 125
- Downloads 0
Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy
Syncope during boceprevir treatment in hepatitis C
Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
Background. Liver stiffness measurement (LSM) using Fibroscan® is an increasingly popular non-invasive method for quantifying liver fibrosis in patients with chronic viral hepatitis. We aimed to explore potential impact...
Hepatic portal venous gas
Cardiac metastasis of hepatocellular carcinoma in a young non-cirrhotic patient, to the left ventricle
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. 1,2 The most common extrahepatic metastatic sites are lung, abdominal lymph nodes and bone, while its cardiac metastasis is rare. 2,3Metasta...